181 related articles for article (PubMed ID: 29363363)
1. Nivolumab for the treatment of urothelial cancers.
Teo MY; Rosenberg JE
Expert Rev Anticancer Ther; 2018 Mar; 18(3):215-221. PubMed ID: 29363363
[TBL] [Abstract][Full Text] [Related]
2. Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.
Kurtoglu M; Davarpanah NN; Qin R; Powles T; Rosenberg JE; Apolo AB
Clin Genitourin Cancer; 2015 Oct; 13(5):410-20. PubMed ID: 25862322
[TBL] [Abstract][Full Text] [Related]
3. Targeting advanced urothelial carcinoma-developing strategies.
Alhalabi O; Rafei H; Shah A; Siefker-Radtke A; Campbell M; Gao J
Curr Opin Oncol; 2019 May; 31(3):207-215. PubMed ID: 30844889
[TBL] [Abstract][Full Text] [Related]
4. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.
Lei Q; Wang D; Sun K; Wang L; Zhang Y
Front Cell Dev Biol; 2020; 8():672. PubMed ID: 32793604
[TBL] [Abstract][Full Text] [Related]
5. CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer.
Oshima K; Shoji H; Boku N; Hirano H; Okita N; Takashima A; Kato K; Kudo-Saito C
Am J Cancer Res; 2024; 14(3):1174-1189. PubMed ID: 38590413
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.
Garde-Noguera J; Martin-Martorell P; De Julián M; Perez-Altozano J; Salvador-Coloma C; García-Sanchez J; Insa-Molla A; Martín M; Mielgo-Rubio X; Marin-Liebana S; Blasco-Cordellat A; Blasco-Molla S; Gironés R; Marquez-Medina D; Aparisi F; Cerda MCB; Macia-Escalante S; Sánchez A; Juan-Vidal O
Clin Transl Oncol; 2018 Aug; 20(8):1072-1079. PubMed ID: 29368144
[TBL] [Abstract][Full Text] [Related]
7. Role of immunotherapy in bladder cancer: past, present and future.
Butt SU; Malik L
Cancer Chemother Pharmacol; 2018 Apr; 81(4):629-645. PubMed ID: 29368051
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
Zhu J; Armstrong AJ; Friedlander TW; Kim W; Pal SK; George DJ; Zhang T
J Immunother Cancer; 2018 Jan; 6(1):4. PubMed ID: 29368638
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors for metastatic bladder cancer.
Massari F; Di Nunno V; Cubelli M; Santoni M; Fiorentino M; Montironi R; Cheng L; Lopez-Beltran A; Battelli N; Ardizzoni A
Cancer Treat Rev; 2018 Mar; 64():11-20. PubMed ID: 29407369
[TBL] [Abstract][Full Text] [Related]
10. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.
Diehl A; Yarchoan M; Hopkins A; Jaffee E; Grossman SA
Oncotarget; 2017 Dec; 8(69):114268-114280. PubMed ID: 29371985
[TBL] [Abstract][Full Text] [Related]
11. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS; Barata PC; Zhang T; George DJ; Atkins MB; Kelly WJ; Vogelzang NJ; Pal SK; Hsu J; Appleman LJ; Ornstein MC; Gilligan T; Grivas P; Garcia JA; Rini BI
J Immunother Cancer; 2018 Jan; 6(1):9. PubMed ID: 29378660
[TBL] [Abstract][Full Text] [Related]
12. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
13. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
[TBL] [Abstract][Full Text] [Related]
14. Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.
George DJ; Martini JF; Staehler M; Motzer RJ; Magheli A; Escudier B; Gerletti P; Li S; Casey M; Laguerre B; Pandha HS; Pantuck AJ; Patel A; Lechuga MJ; Ravaud A
Clin Cancer Res; 2018 Apr; 24(7):1554-1561. PubMed ID: 29374054
[No Abstract] [Full Text] [Related]
15. New drugs and new toxicities: pembrolizumab-induced myocarditis.
Inayat F; Masab M; Gupta S; Ullah W
BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29367376
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Vokes EE; Ready N; Felip E; Horn L; Burgio MA; Antonia SJ; Arén Frontera O; Gettinger S; Holgado E; Spigel D; Waterhouse D; Domine M; Garassino M; Chow LQM; Blumenschein G; Barlesi F; Coudert B; Gainor J; Arrieta O; Brahmer J; Butts C; Steins M; Geese WJ; Li A; Healey D; Crinò L
Ann Oncol; 2018 Apr; 29(4):959-965. PubMed ID: 29408986
[TBL] [Abstract][Full Text] [Related]
17. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
18. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F
Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination.
Fiorica F; Belluomini L; Stefanelli A; Santini A; Urbini B; Giorgi C; Frassoldati A
Am J Clin Oncol; 2018 Nov; 41(11):1101-1105. PubMed ID: 29389733
[TBL] [Abstract][Full Text] [Related]
20. Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center.
Lisberg A; Tucker DA; Goldman JW; Wolf B; Carroll J; Hardy A; Morris K; Linares P; Adame C; Spiegel ML; Wells C; McKenzie J; Ledezma B; Mendenhall M; Abarca P; Bornazyan K; Hunt J; Moghadam N; Chong N; Nameth D; Marx C; Madrigal J; Vangala S; Shaverdian N; Elashoff D; Garon EB
Cancer Immunol Res; 2018 Mar; 6(3):288-294. PubMed ID: 29382669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
